AI Engines For more Details: Perplexity Kagi Labs You
Symptom Relief: Biperiden hydrochloride helps alleviate symptoms of Parkinson's disease and other movement disorders by blocking the action of acetylcholine, a neurotransmitter involved in motor control. This can help improve muscle stiffness, tremors, and involuntary movements associated with these conditions.
Anticholinergic Effects: Biperiden hydrochloride belongs to a class of medications known as anticholinergics, which block the effects of acetylcholine in the brain and peripheral nervous system. This can lead to a reduction in symptoms such as muscle rigidity and excessive salivation.
Parkinson's Disease: Biperiden hydrochloride is often used as an adjunctive therapy in Parkinson's disease, particularly in patients experiencing tremors, muscle stiffness, and other motor symptoms not adequately controlled by other medications.
Extrapyramidal Symptoms: It is also used to manage extrapyramidal symptoms (EPS) caused by antipsychotic medications, which include drug-induced movement disorders such as dystonia, akathisia, and parkinsonism.
Dosage: The dosage of biperiden hydrochloride varies depending on the individual's age, weight, and the severity of their symptoms. It is typically taken orally in tablet or liquid form, but it may also be administered via injection in certain situations.
Side Effects: Common side effects of biperiden hydrochloride include dry mouth, blurred vision, constipation, urinary retention, dizziness, drowsiness, and confusion. These side effects are usually mild and transient but may require medical attention if they persist or worsen.
Contraindications: Biperiden hydrochloride is contraindicated in individuals with a history of hypersensitivity to the medication, narrow-angle glaucoma, or certain gastrointestinal conditions such as paralytic ileus. It should be used with caution in elderly patients and those with conditions such as prostatic hypertrophy and urinary retention.
Drug Interactions: Biperiden hydrochloride may interact with other medications, including antipsychotics, antidepressants, antihistamines, and certain antibiotics. It's important to consult a healthcare provider or pharmacist before taking biperiden hydrochloride concurrently with other medications.
Monitoring: Patients taking biperiden hydrochloride may require regular monitoring of their symptoms, as well as their electrolyte levels, renal function, and cognitive status. Adjustments to the dosage may be necessary based on individual response and tolerability.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium longum | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
| Acne | 0.6 | 0.4 | 0.5 |
| ADHD | 1.8 | 0.6 | 2 |
| Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.6 | |
| Allergic Rhinitis (Hay Fever) | 1.4 | 0.9 | 0.56 |
| Allergies | 2.4 | 2.3 | 0.04 |
| Allergy to milk products | 1.8 | 0.6 | 2 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 3.3 | 2.9 | 0.14 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.1 | 0.9 | 2.44 |
| Ankylosing spondylitis | 2.5 | 1 | 1.5 |
| Anorexia Nervosa | 0.7 | 1.7 | -1.43 |
| Antiphospholipid syndrome (APS) | 0.1 | 0.1 | |
| Asthma | 2.5 | 1.8 | 0.39 |
| Atherosclerosis | 1.2 | 0.6 | 1 |
| Atrial fibrillation | 2.8 | 0.9 | 2.11 |
| Autism | 5.1 | 5.1 | 0 |
| Autoimmune Disease | 0.3 | 0.3 | 0 |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.4 | 0.4 | |
| Bipolar Disorder | 0.6 | 0.9 | -0.5 |
| Brain Trauma | 0.6 | 0.9 | -0.5 |
| Breast Cancer | 0.6 | 0.3 | 1 |
| Cancer (General) | 0.6 | 0.6 | 0 |
| Carcinoma | 2.2 | 2.2 | 0 |
| Celiac Disease | 1.1 | 3.1 | -1.82 |
| Cerebral Palsy | 1.2 | 0.7 | 0.71 |
| Chronic Fatigue Syndrome | 2.2 | 2.9 | -0.32 |
| Chronic Kidney Disease | 2.1 | 1.6 | 0.31 |
| Chronic Lyme | 0.5 | 0.3 | 0.67 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 0.9 | -0.5 |
| Chronic Urticaria (Hives) | 0.3 | 0.7 | -1.33 |
| Coagulation / Micro clot triggering bacteria | 0.4 | -0.4 | |
| Cognitive Function | 1.8 | 0.6 | 2 |
| Colorectal Cancer | 4.5 | 1.4 | 2.21 |
| Constipation | 1 | 0.2 | 4 |
| Coronary artery disease | 1 | 1.7 | -0.7 |
| COVID-19 | 2.9 | 5.1 | -0.76 |
| Crohn's Disease | 3.4 | 4.7 | -0.38 |
| Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
| cystic fibrosis | 0.7 | -0.7 | |
| deep vein thrombosis | 1.2 | 0.6 | 1 |
| Denture Wearers Oral Shifts | 0.1 | 0.1 | |
| Depression | 4.7 | 5.5 | -0.17 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 0.4 | 0.4 | 0 |
| Endometriosis | 1.6 | 1.5 | 0.07 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 1.4 | 1.7 | -0.21 |
| erectile dysfunction | 0.4 | 0.3 | 0.33 |
| Fibromyalgia | 1 | 0.9 | 0.11 |
| Functional constipation / chronic idiopathic constipation | 2.3 | 1.4 | 0.64 |
| gallstone disease (gsd) | 1.5 | 0.7 | 1.14 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.3 | 0.67 |
| Generalized anxiety disorder | 1.2 | 1.5 | -0.25 |
| Gout | 1 | 1 | 0 |
| Graves' disease | 1.5 | 2.5 | -0.67 |
| Gulf War Syndrome | 0.4 | 1.5 | -2.75 |
| Halitosis | 0.6 | 0.6 | |
| Hashimoto's thyroiditis | 2.4 | 1.3 | 0.85 |
| Heart Failure | 2.1 | 1.4 | 0.5 |
| hemorrhagic stroke | 0.6 | 0.6 | |
| Hidradenitis Suppurativa | 0.6 | 0.3 | 1 |
| High Histamine/low DAO | 0.6 | -0.6 | |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.6 | -1 |
| hyperglycemia | 0.7 | 1.7 | -1.43 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 3.2 | 3 | 0.07 |
| Hypothyroidism | 0.4 | 0.7 | -0.75 |
| Hypoxia | 1.5 | 0.3 | 4 |
| IgA nephropathy (IgAN) | 0.6 | 1.6 | -1.67 |
| Inflammatory Bowel Disease | 2.5 | 4.2 | -0.68 |
| Insomnia | 1.6 | 2.6 | -0.63 |
| Intelligence | 0.6 | 0.6 | |
| Intracranial aneurysms | 0.7 | 0.9 | -0.29 |
| Irritable Bowel Syndrome | 3.3 | 3.2 | 0.03 |
| ischemic stroke | 1.9 | 0.6 | 2.17 |
| Liver Cirrhosis | 3.3 | 3.6 | -0.09 |
| Long COVID | 3.7 | 4.6 | -0.24 |
| Low bone mineral density | 0.6 | -0.6 | |
| Lung Cancer | 1.6 | -1.6 | |
| Mast Cell Issues / mastitis | 0.9 | -0.9 | |
| ME/CFS with IBS | 0.5 | 1 | -1 |
| ME/CFS without IBS | 0.1 | 1.2 | -11 |
| Menopause | 0.4 | 0.4 | 0 |
| Metabolic Syndrome | 3 | 4.2 | -0.4 |
| Mood Disorders | 4.6 | 4.3 | 0.07 |
| multiple chemical sensitivity [MCS] | 0.7 | 0.1 | 6 |
| Multiple Sclerosis | 2.7 | 2.4 | 0.13 |
| Multiple system atrophy (MSA) | 1 | 0.7 | 0.43 |
| neuropathic pain | 1.4 | -1.4 | |
| Neuropathy (all types) | 0.5 | 0.1 | 4 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.3 | 3.4 | -0.48 |
| NonCeliac Gluten Sensitivity | 1.6 | 0.6 | 1.67 |
| Obesity | 5 | 5 | 0 |
| obsessive-compulsive disorder | 1.8 | 2.9 | -0.61 |
| Osteoarthritis | 0.5 | 1.2 | -1.4 |
| Osteoporosis | 0.9 | 1.6 | -0.78 |
| pancreatic cancer | 0.3 | 0.3 | |
| Parkinson's Disease | 3.8 | 3.1 | 0.23 |
| Polycystic ovary syndrome | 1.8 | 1.8 | 0 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.7 | 0.7 | |
| primary biliary cholangitis | 0.9 | 0.3 | 2 |
| Primary sclerosing cholangitis | 0.7 | 0.8 | -0.14 |
| Psoriasis | 1.5 | 1.5 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.4 | 2.8 | 0.21 |
| Rosacea | 0.7 | 0.3 | 1.33 |
| Schizophrenia | 3.4 | 2.2 | 0.55 |
| scoliosis | 0.3 | 0.9 | -2 |
| Sjögren syndrome | 0.8 | 1.6 | -1 |
| Sleep Apnea | 1.9 | 1 | 0.9 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.2 | 3.5 |
| Stress / posttraumatic stress disorder | 1.5 | 1.8 | -0.2 |
| Systemic Lupus Erythematosus | 1.5 | 1.3 | 0.15 |
| Tic Disorder | 0.7 | 1.2 | -0.71 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 2.2 | 1.9 | 0.16 |
| Type 2 Diabetes | 4.3 | 3.9 | 0.1 |
| Ulcerative colitis | 2.2 | 3.3 | -0.5 |
| Unhealthy Ageing | 2.8 | 1.5 | 0.87 |
| Vitiligo | 1.2 | 1 | 0.2 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
